File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/mtm.2015.35
- Scopus: eid_2-s2.0-84960386600
- WOS: WOS:000209918700047
Supplementary
- Citations:
- Appears in Collections:
Article: A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9
Title | A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9 |
---|---|
Authors | |
Issue Date | 2015 |
Citation | Molecular Therapy - Methods and Clinical Development, 2015, v. 2, p. 15035 How to Cite? |
Abstract | © 2015 Official journal of the American Society of Gene & Cell Therapy The current method for creation of vaccinia virus (VACV) vectors involves using a selection and purification marker, however inclusion of a gene without therapeutic value in the resulting vector is not desirable for clinical use. The Cre-LoxP system has been used to make marker-free Poxviruses, but the efficiency was very low. To obtain a marker-free VACV vector, we developed marker gene excision systems to modify the thymidine kinase (TK) regi on and N1L regions using Cre-Loxp and Flp-FRET systems respectively. CRISPR-Cas9 system significantly resulted in a high efficiency (⠼90%) in generation of marker gene-positive TK-mutant VACV vector. The marker gene (RFP) could be excised from the recombinant virus using Cre recombinase. To make a marker-free VV vector with double gene deletions targeting the TK and N1L gene, we constructed a donor repair vector targeting the N1L gene, which can carry a therapeutic gene and the marker (RFP) that could be excised from the recombinant virus using Flp recombinase. The marker-free system developed here can be used to efficiently construct VACV vectors armed with any therapeutic genes in the TK region or N1L region without marker genes. Our marker-free system platform has significant potential for development of new marker-free VACV vectors for clinical application. |
Persistent Identifier | http://hdl.handle.net/10722/249118 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yuan, Ming | - |
dc.contributor.author | Gao, Xuefei | - |
dc.contributor.author | Chard, Louisa S. | - |
dc.contributor.author | Ali, Zarah | - |
dc.contributor.author | Ahmed, Jahangir | - |
dc.contributor.author | Li, Yunqing | - |
dc.contributor.author | Liu, Pentao | - |
dc.contributor.author | Lemoine, Nick R. | - |
dc.contributor.author | Wang, Yaohe | - |
dc.date.accessioned | 2017-10-27T05:59:09Z | - |
dc.date.available | 2017-10-27T05:59:09Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Molecular Therapy - Methods and Clinical Development, 2015, v. 2, p. 15035 | - |
dc.identifier.uri | http://hdl.handle.net/10722/249118 | - |
dc.description.abstract | © 2015 Official journal of the American Society of Gene & Cell Therapy The current method for creation of vaccinia virus (VACV) vectors involves using a selection and purification marker, however inclusion of a gene without therapeutic value in the resulting vector is not desirable for clinical use. The Cre-LoxP system has been used to make marker-free Poxviruses, but the efficiency was very low. To obtain a marker-free VACV vector, we developed marker gene excision systems to modify the thymidine kinase (TK) regi on and N1L regions using Cre-Loxp and Flp-FRET systems respectively. CRISPR-Cas9 system significantly resulted in a high efficiency (⠼90%) in generation of marker gene-positive TK-mutant VACV vector. The marker gene (RFP) could be excised from the recombinant virus using Cre recombinase. To make a marker-free VV vector with double gene deletions targeting the TK and N1L gene, we constructed a donor repair vector targeting the N1L gene, which can carry a therapeutic gene and the marker (RFP) that could be excised from the recombinant virus using Flp recombinase. The marker-free system developed here can be used to efficiently construct VACV vectors armed with any therapeutic genes in the TK region or N1L region without marker genes. Our marker-free system platform has significant potential for development of new marker-free VACV vectors for clinical application. | - |
dc.language | eng | - |
dc.relation.ispartof | Molecular Therapy - Methods and Clinical Development | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9 | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1038/mtm.2015.35 | - |
dc.identifier.scopus | eid_2-s2.0-84960386600 | - |
dc.identifier.volume | 2 | - |
dc.identifier.spage | 15035 | - |
dc.identifier.eissn | 2329-0501 | - |
dc.identifier.isi | WOS:000209918700047 | - |
dc.identifier.issnl | 2329-0501 | - |